{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:47:11Z","timestamp":1787237231899,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T00:00:00Z","timestamp":1437782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ministry of Education, Science and Technology (MEST) of Republic of Kosova","award":["2-4447"],"award-info":[{"award-number":["2-4447"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00774-015-0699-6","type":"journal-article","created":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T09:29:48Z","timestamp":1437730188000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors"],"prefix":"10.1007","volume":"34","author":[{"given":"Elton","family":"Bahtiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmi","family":"Islami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rexhep","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasime","family":"Qorraj-Bytyqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylejman","family":"Rexhepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreshnik","family":"Hoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kujtim","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shpetim","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fla","family":"Karakulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,25]]},"reference":[{"key":"699_CR1","volume-title":"Basic and clinical pharmacology","year":"2012","unstructured":"Katzung BG, Masters SB, Trevor AJ (eds) (2012) Basic and clinical pharmacology, 12th edn. McGraw-Hill, New York","edition":"12"},{"key":"699_CR2","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","year":"2011","unstructured":"Brunton LL, Chabner BA, Knollmann BC (eds) (2011) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York","edition":"12"},{"key":"699_CR3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003495-200868070-00004","volume":"68","author":"V Boparai","year":"2008","unstructured":"Boparai V, Rajagopalan J, Triadafilopoulos G (2008) Guide to the use of proton pump inhibitors in adult patients. Drugs 68:925\u2013947","journal-title":"Drugs"},{"key":"699_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","volume":"23","author":"G Sachs","year":"2006","unstructured":"Sachs G, Shin JM, Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23:2\u20138","journal-title":"Aliment Pharmacol Ther"},{"key":"699_CR5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","volume":"64","author":"S Shi","year":"2008","unstructured":"Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935\u2013951","journal-title":"Eur J Clin Pharmacol"},{"key":"699_CR6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjmed.2009.04.014","volume":"122","author":"T Ali","year":"2009","unstructured":"Ali T, Roberts DN, Tierney WM (2009) Long-term safety concerns with proton pump inhibitors. Am J Med 122:896\u2013903","journal-title":"Am J Med"},{"key":"699_CR7","volume-title":"Regjistri i barnave","author":"A Jakupi","year":"2014","unstructured":"Jakupi A, Krasniqi S, Hoxha R (2014) Regjistri i barnave, 3rd edn. Prishtina, Kosovo","edition":"3"},{"key":"699_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1060028014558290","volume":"49","author":"E Reeve","year":"2015","unstructured":"Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S (2015) The feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother 49:29\u201338","journal-title":"Ann Pharmacother"},{"key":"699_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bpg.2013.06.001","volume":"27","author":"C Reimer","year":"2013","unstructured":"Reimer C (2013) Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 27:443\u2013454","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"699_CR10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MAJ.0b013e31829f87d5","volume":"347","author":"AM Ladd","year":"2014","unstructured":"Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R (2014) Inappropriate use of proton pump inhibitors and its potential costs in low risk patients. Am J Med Sci 347:446\u2013451","journal-title":"Am J Med Sci"},{"key":"699_CR11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1742-1241.2012.02921.x","volume":"66","author":"JJ Heidelbaugh","year":"2012","unstructured":"Heidelbaugh JJ, Metz DC, Yang Y-X (2012) Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 66:582\u2013591","journal-title":"Int J Clin Pract"},{"key":"699_CR12","unstructured":"Jakupi A (2014) Drug consumption in Kosovo 2011\u20132013. Kosovo"},{"key":"699_CR13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000331519","volume":"29","author":"B Tepe\u0161","year":"2011","unstructured":"Tepe\u0161 B (2011) Long-term acid inhibition: benefits and harms. Dig Dis 29:476\u2013481","journal-title":"Dig Dis"},{"key":"699_CR14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cgh.2013.05.034","volume":"11","author":"S Medlo","year":"2013","unstructured":"Medlo S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, Abu-Hanna A (2013) Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol 11:1259\u20131269.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"699_CR15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/papr.12100","volume":"14","author":"RA Moore","year":"2014","unstructured":"Moore RA, Derry S, Simon LS, Emery P (2014) Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract 14:378\u2013395","journal-title":"Pain Pract"},{"key":"699_CR16","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar4177","volume":"15","author":"JM Scheiman","year":"2013","unstructured":"Scheiman JM (2013) The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 15:S5","journal-title":"Arthritis Res Ther"},{"key":"699_CR17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2169\/internalmedicine.53.2159","volume":"53","author":"Y Sakamoto","year":"2014","unstructured":"Sakamoto Y, Shimoyama T, Nakagawa S, Mikami T, Fukuda S (2014) Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. Intern Med 53:1107\u20131111","journal-title":"Intern Med"},{"key":"699_CR18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-010-1560-3","volume":"56","author":"E Sheen","year":"2011","unstructured":"Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56:931\u2013950","journal-title":"Dig Dis Sci"},{"key":"699_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000031","volume":"21","author":"V Corleto","year":"2014","unstructured":"Corleto V, Festa S, Di Giulio E, Annibale B (2014) Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 21:3\u20138","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"699_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","volume":"84","author":"C Roux","year":"2009","unstructured":"Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, Reid DM, Eastell R, Gl\u00fcer CC (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13\u201319","journal-title":"Calcif Tissue Int"},{"key":"699_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2042098613482484","volume":"4","author":"JJ Heidelbaugh","year":"2013","unstructured":"Heidelbaugh JJ (2013) Proton pump inhibitors and risks of mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 4:125\u2013133","journal-title":"Ther Adv Drug Saf"},{"key":"699_CR22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-012-2112-9","volume":"24","author":"L-A Fraser","year":"2013","unstructured":"Fraser L-A, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group (2013) The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int 24:1161\u20131168","journal-title":"Osteoporos Int"},{"key":"699_CR23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11894-012-0290-4","volume":"14","author":"Y-X Yang","year":"2012","unstructured":"Yang Y-X (2012) Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep 14:473\u2013479","journal-title":"Curr Gastroenterol Rep"},{"key":"699_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","volume":"139","author":"DA Corley","year":"2010","unstructured":"Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139:93\u2013101","journal-title":"Gastroenterology"},{"key":"699_CR25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bone.2013.09.014","volume":"57","author":"M Maggio","year":"2013","unstructured":"Maggio M, Lauretani F, Ceda GP et al (2013) Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57:437\u2013442","journal-title":"Bone"},{"key":"699_CR26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jbmr.2344","volume":"30","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Diem SJ, Ruppert K, Lian YJ, Wohlfart A, Greendale GA, Finkelstein JS (2015) Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a swan cohort study. J Bone Miner Res 30:232\u2013239","journal-title":"J Bone Miner Res"},{"key":"699_CR27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.maturitas.2014.05.019","volume":"78","author":"LME Moberg","year":"2014","unstructured":"Moberg LME, Nilsson PM, Samsioe G, Borgfeldt C (2014) Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas 78:310\u2013315","journal-title":"The WHILA study. Maturitas"},{"key":"699_CR28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s00296-013-2709-0","volume":"33","author":"K Ozdil","year":"2013","unstructured":"Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH (2013) Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int 33:2255\u20132260","journal-title":"Rheumatol Int"},{"key":"699_CR29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1517\/14740338.2011.586628","volume":"10","author":"LE Targownik","year":"2011","unstructured":"Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 10:901\u2013912","journal-title":"Expert Opin Drug Saf"},{"key":"699_CR30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/jbmr.108","volume":"25","author":"MJ Wright","year":"2010","unstructured":"Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O\u2019Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 25:2205\u20132211","journal-title":"J Bone Miner Res"},{"key":"699_CR31","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","volume":"118","author":"MB O\u2019Connell","year":"2005","unstructured":"O\u2019Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778\u2013781","journal-title":"Am J Med"},{"key":"699_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.abb.2008.03.025","volume":"476","author":"KC Jefferies","year":"2008","unstructured":"Jefferies KC, Cipriano DJ, Forgac M (2008) Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys 476:33\u201342","journal-title":"Arch Biochem Biophys"},{"key":"699_CR33","first-page":"1111","volume":"43","author":"M Herrmann","year":"2005","unstructured":"Herrmann M, Widmann T, Herrmann W (2005) Homocysteine\u2014a newly recognised risk factor for osteoporosis. Clin Chem Lab Med 43:1111\u20131117","journal-title":"Clin Chem Lab Med"},{"key":"699_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00223-009-9244-8","volume":"84","author":"BL Vaes","year":"2009","unstructured":"Vaes BL, Lute C, Blom HJ, Bravenboer N, de Vries TJ, Everts V, Dhonukshe-Rutten RA, M\u00fcller M, de Groot LC, Steegenga WT (2009) Vitamin B12 deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid. Calcif Tissue Int 84:413\u2013422","journal-title":"Calcif Tissue Int"},{"key":"699_CR35","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/ajg.2012.200","volume":"107","author":"LE Targownik","year":"2012","unstructured":"Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W, CaMos Research Group (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361\u20131369","journal-title":"Am J Gastroenterol"},{"key":"699_CR36","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"P Miner","year":"2003","unstructured":"Miner P, Katz PO, Chen Y, Sostek M (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 98:2616\u20132620","journal-title":"Am J Gastroenterol"},{"key":"699_CR37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-004-0804-6","volume":"60","author":"K R\u00f6hss","year":"2004","unstructured":"R\u00f6hss K, Lind T, Wilder-Smith C (2004) Esomeprazole 40\u00a0mg provides more effective intragastric acid control than lansoprazole 30\u00a0mg, omeprazole 20\u00a0mg, pantoprazole 40\u00a0mg and rabeprazole 20\u00a0mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 60:531\u2013539","journal-title":"Eur J Clin Pharmacol"},{"key":"699_CR38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1345\/aph.1R556","volume":"47","author":"CP Luk","year":"2013","unstructured":"Luk CP, Parsons R, Lee YP, Hughes JD (2013) Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 47:773\u2013780","journal-title":"Ann Pharmacother"},{"key":"699_CR39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","volume":"83","author":"EW Yu","year":"2008","unstructured":"Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251\u2013259","journal-title":"Calcif Tissue Int"},{"key":"699_CR40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","volume":"170","author":"SL Gray","year":"2010","unstructured":"Gray SL, LaCroix A, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women\u2019s Health Initiative. Arch Intern Med 170:765\u2013771","journal-title":"Arch Intern Med"},{"key":"699_CR41","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/jbmr.2279","volume":"29","author":"JR Lewis","year":"2014","unstructured":"Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29:2489\u20132497","journal-title":"J Bone Miner Res"},{"key":"699_CR42","unstructured":"US Food and Drug Adminsitration (2011) FDA drug safety communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm213206.htm . Accessed 8 Dec 2014"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-015-0699-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-015-0699-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-015-0699-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T13:47:13Z","timestamp":1567000033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-015-0699-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,25]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s00774-015-0699-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,25]]}}}